drugset / Trial / NCT01170702

Transverse Abdominis Plane (TAP) Block After Cesarean Delivery

NCT01170702 ↗

Phase 4 Completed 120 enrolled Northwestern University
RandomizedParallel-groupDouble-blindTreatment

Summary

Since there have been no published dose-response studies investigating the effective analgesic dose of ropivacaine for use in a TAP block for post-Cesarean delivery analgesia, the investigators propose a study primarily examining the effect on 24 hour post-Cesarean delivery opioid consumption of using either a placebo, 0.25% ropivacaine, 0.5% ropivacaine, or 0.75% ropivacaine for TAP blocks.

Timeline

Start
2010-01
Primary completion
2017-01
Completion
2017-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropivacaine Other / unclassified 0.2 % Other
Subject Ropivacaine Other / unclassified 0.5 % Other
Subject Ropivacaine Other / unclassified 0.75 % Other